Almac selected as preferred partner for EORTC clinical trials

By Melissa Fassbender contact

- Last updated on GMT

Almac selected as preferred partner for EORTC clinical trials

Related tags: Cancer

Almac Diagnostics will initiate sample profiling on current EORTC trials to further biomarker discovery and development.

Through the partnership, Almac Diagnostics will support molecular profiling of cancer patient samples collected by the European Organization for the Research and Treatment of Cancer (EORTC) and SPECTA (Screening Patients for Effective Clinical Trial Access).

"The ​SPECTA Program team require a partner to provide consistent, quality analysis of samples from their clinical trials​," Michael Sloan, VP Business Development, Almac Diagnostics, told

"They sought a partner who can provide a robust quality service and support the discovery, development and ultimately commercialization of biomarkers​."

Specifically, Almac Diagnostics will analyze patterns of genomic variation within patient samples using the new Illumina Trusight Tumor 170 solid tumor NGS panel.

"This partnership will provide a consistent approach to biomarker discovery and development from these valuable European clinical trial samples​," added Sloan.

The partnership is set to last for an "indefinite period of time," ​Sloan explained, and no further investment is required on Almac's part as the company has "significant​" capacity available. 

The services will be provided from Almac’s European facility in Craigavon, Northern Ireland.

The SPECTA infrastructure

Vassilis Golfinopoulos, EORTC Medical Director said the agreement with Almac is one of “several key partnership​” established to advance the SPECTA infrastructure.

The organization ultimately hopes to simplify patient inclusion in clinical trials of molecularly targeted treatment.

It is also looking to standardize Next Generation Sequencing (NGS) and Gene Expression Analysis in translational research projects in order to improve reproducibility and comparability of results.

(Feature image: iStock/manaemedia)

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more